We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)
Neurogastroenterol. Motil. 2023 Feb 05;[EPub Ahead of Print], L Chang, BD Cash, A Lembo, DC Kunkel, BA English, B Lindstrom, G Gu, S Skare, K Gilder, S Turner, F Cataldi, D Lipkis, T Jan